{"id":"abrocitinib-tablet","safety":{"safetySignals":[{"date":"","signal":"ASTHMA","source":"FDA FAERS","actionTaken":"Reported 1 times"},{"date":"","signal":"LUNG OPACITY","source":"FDA FAERS","actionTaken":"Reported 1 times"}],"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Live vaccines","action":"Avoid","effect":"Decreased response to vaccine"},{"drug":"Bacillus Calmette-Guérin (BCG) vaccine","action":"Avoid","effect":"Decreased response to vaccine"},{"drug":"Other vaccines","action":"Avoid","effect":"Decreased response to vaccine"},{"drug":"Immunosuppressants","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Methotrexate","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Biologics","action":"Monitor","effect":"Increased risk of infections"},{"drug":"TNF-alpha inhibitors","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Anakinra","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Rituximab","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Other immunosuppressants","action":"Monitor","effect":"Increased risk of infections"},{"drug":"CYP3A4 inhibitors","action":"Monitor","effect":"Increased levels of abrocitinib"},{"drug":"CYP3A4 inducers","action":"Monitor","effect":"Decreased levels of abrocitinib"}],"commonSideEffects":[],"contraindications":["Allergies to Ingredients. People who are allergic to any of the following should not take Cibinqo. - Cibinqo\n- Abrocitinib\n- Any of the ingredients in the specific product dispensed\n\nWho should not use Cibinqo? Allergies to Ingredients. People who are allergic to any of the following should not take Cibinqo.\n\nDrug Interactions. Cibinqo should not be taken while you are using certain other medicines. Before taking Cibinqo, tell\n\nKidney Problems. Cibinqo should not be used if your kidneys are not working as well as they should be. If there is a concern about the health of your kidneys, your healthcare provider may do tests to determine if they are working well enough to take this medicine.\nLiver Problems. Cibinqo should not be used if your liver is not working as well as it should be. If there is a concern\n\n### What should I know about Cibinqo before using it? Do not take Cibinqo unless it has been prescribed to you by a healthcare provider. Take it as prescribed.\n\nCibinqo can affect your alertness or coordination. Do not drive or do other activities that require alertness or\n\nif you have recently received a live vaccine or have any scheduled. Current and Past Health Conditions. Tell your healthcare provider if you have any of the following.\n- Being treated for an infection or having symptoms of an infection\n- Have an infection that will not go away or keeps coming back\n- Diabetes\n- Chronic lung disease, such as asthma or chronic obstructive lung disease (COPD)\n- Shingles\n- Cancer\n- Blood clots in your legs or lungs\n- Tuberculosis (T"],"specialPopulations":{"Pregnancy":"Cibinqo is contraindicated during pregnancy. There are no or limited amount of data on the use of abrocitinib in pregnant women. Studies in animals have shown reproductive toxicity.","Geriatric use":"For patients 65 years of age and older, the recommended dose is 100 mg once daily.","Paediatric use":"The safety and efficacy of Cibinqo in children under 12 years of age have not yet been established.","Renal impairment":"adjustment is required in patients with mild renal impairment, i.e. estimated glomerular filtration rate (eGFR) ≥ 50 mL/min.","Hepatic impairment":"No dose adjustment is required in patients with mild (Child Pugh A) or moderate (Child Pugh B) hepatic impairment. Abrocitinib is contraindicated to patients with severe (Child Pugh C) hepatic impairment."}},"_chembl":null,"company":"Pfizer","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=abrocitinib-tablet","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:56:53.783266+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:57:00.717388+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:56:53.804498+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=abrocitinib-tablet","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:57:01.486034+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Tyrosine-protein kinase JAK1 inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:57:02.050814+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3655081/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:57:01.955857+00:00"}},"allNames":"abrocitinib tablet","timeline":[],"_dailymed":null,"aiSummary":"Abrocitinib tablet, developed by Pfizer Inc., is a marketed drug for moderate to severe atopic dermatitis in adults. It has a mechanism of action that targets the JAK1 enzyme, which plays a key role in inflammation. Abrocitinib has shown clinical differentiation from other treatments due to its efficacy in patients who have had an inadequate response or intolerance to biologics. The commercial significance of Abrocitinib is substantial, with revenue of $63.6B. The pipeline developments for Abrocitinib are focused on its continued use in treating atopic dermatitis. Abrocitinib's mechanism of action and clinical differentiation make it a valuable treatment option for patients with moderate to severe atopic dermatitis.","brandName":"Abrocitinib tablet","isGeneric":true,"mechanism":{"target":"JAK1","novelty":"best-in-class","modality":"small molecule","drugClass":"JAK inhibitor","explanation":"","oneSentence":"","technicalDetail":"Abrocitinib is a selective JAK1 inhibitor that has been shown to reduce inflammation in patients with atopic dermatitis. The drug's mechanism of action is based on its ability to inhibit the JAK1 enzyme, which is a key player in the signaling pathways that lead to inflammation. Abrocitinib's efficacy has been demonstrated in clinical trials, where it has shown significant improvements in symptoms and quality of life for patients with atopic dermatitis."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:58.805Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"yoyGrowth":"7%","revenueYear":2025,"annualCostUS":"$80,000/yr","annualRevenue":284,"genericStatus":"Generic — off-patent","revenueSource":"SEC 8-K Pfizer (2026-02-03)","currentRevenue":"","revenueCurrency":"USD","peakSalesEstimate":"","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T10:48:50.281182","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=abrocitinib-tablet","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=abrocitinib-tablet","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":5,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":6,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:57:03.890046+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"competitors":[{"name":"Dupixent (dupilumab)","company":"Sanofi and Regeneron Pharmaceuticals","advantage":"Longer duration of action and alternative administration route (injection)"},{"name":"Ebglyss (lebrikizumab)","company":"Novartis","advantage":"Alternative Janus kinase (JAK) inhibitor for atopic dermatitis treatment"},{"name":"Triamcinolone topical","company":"Various manufacturers","advantage":"Lower cost and topical administration for localized treatment"},{"name":"Clobetasol topical","company":"Various manufacturers","advantage":"Higher potency and topical administration for localized treatment"},{"name":"Tacrolimus topical","company":"Various manufacturers","advantage":"Alternative immunosuppressive treatment for atopic dermatitis"},{"name":"Dupilumab","company":"Sanofi and Regeneron Pharmaceuticals","advantage":"Alternative interleukin inhibitor for atopic dermatitis treatment"},{"name":"Betamethasone topical","company":"Various manufacturers","advantage":"Lower cost and topical administration for localized treatment"}],"genericName":"abrocitinib-tablet","indications":{"approved":[{"name":"Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"trialDetails":[{"nctId":"NCT05387980","phase":"","title":"A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-04-19","conditions":"Atopic Dermatitis","enrollment":1128},{"nctId":"NCT06283550","phase":"PHASE2","title":"Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy","status":"COMPLETED","sponsor":"Innovaderm Research Inc.","startDate":"2024-05-31","conditions":"Chronic Hand Eczema","enrollment":82},{"nctId":"NCT03422822","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-03-08","conditions":"Dermatitis, Atopic","enrollment":3166},{"nctId":"NCT06597396","phase":"PHASE2","title":"Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2024-12-27","conditions":"Post-COVID Condition, Fatigue Symptom","enrollment":46},{"nctId":"NCT05391061","phase":"","title":"A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis","status":"RECRUITING","sponsor":"Pfizer","startDate":"2023-01-07","conditions":"Dermatitis, Atopic","enrollment":1100},{"nctId":"NCT05743244","phase":"PHASE2","title":"Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2023-10-19","conditions":"Diabetes Mellitus, Type 1","enrollment":78},{"nctId":"NCT05602207","phase":"PHASE4","title":"Effects of Abrocitinib in Subjects With Atopic Dermatitis With an Unsatisfactory Response After Treatment With Dupilumab","status":"COMPLETED","sponsor":"Innovaderm Research Inc.","startDate":"2022-11-25","conditions":"Atopic Dermatitis","enrollment":24},{"nctId":"NCT04903093","phase":"PHASE1","title":"A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-06-04","conditions":"Healthy Volunteers","enrollment":19},{"nctId":"NCT05375929","phase":"PHASE3","title":"A Study to Learn About Abrocitinib Tablets in People With Atopic Dermatitis in India","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-07-16","conditions":"Atopic Dermatitis","enrollment":200},{"nctId":"NCT06119490","phase":"EARLY_PHASE1","title":"Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis","status":"RECRUITING","sponsor":"Peng Zhang","startDate":"2023-07-05","conditions":"Toxic Epidermal Necrolysis","enrollment":30},{"nctId":"NCT05038982","phase":"PHASE2","title":"Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2021-09-09","conditions":"Prurigo Nodularis, Pruritus, Chronic Pruritus","enrollment":20},{"nctId":"NCT03915496","phase":"PHASE2","title":"Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-18","conditions":"Atopic Dermatitis","enrollment":46},{"nctId":"NCT04345367","phase":"PHASE3","title":"Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-06-11","conditions":"Atopic Dermatitis","enrollment":727},{"nctId":"NCT03627767","phase":"PHASE3","title":"Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-06-11","conditions":"Dermatitis, Dermatitis, Atopic, Eczema","enrollment":1235},{"nctId":"NCT03720470","phase":"PHASE3","title":"Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-10-29","conditions":"Dermatitis, Dermatitis, Atopic, Eczema","enrollment":838},{"nctId":"NCT03575871","phase":"PHASE3","title":"Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-06-29","conditions":"Dermatitis, Atopic","enrollment":391},{"nctId":"NCT03662516","phase":"PHASE1","title":"A Study to Determine the Effects of PF-04965842 on the Pharmacokinetics of Oral Contraceptive Steroids in Healthy Female Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-09-26","conditions":"Healthy Females","enrollment":17},{"nctId":"NCT03796182","phase":"PHASE1","title":"Study of PF 04965842 Effect on MATE1/2K Activity in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-01-10","conditions":"Healthy","enrollment":12},{"nctId":"NCT04099563","phase":"PHASE1","title":"Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-10-14","conditions":"HEALTHY","enrollment":13},{"nctId":"NCT03349060","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-12-07","conditions":"Dermatitis, Atopic","enrollment":387},{"nctId":"NCT02163161","phase":"PHASE1","title":"AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-06","conditions":"Healthy","enrollment":12}],"_emaApprovals":[{"date":"","name":"Abrocitinib tablet","status":"Authorised","regulator":"EMA"}],"_faersSignals":[{"count":1,"reaction":"ASTHMA"},{"count":1,"reaction":"LUNG OPACITY"}],"molecularData":{"oral":true,"chemblId":"CHEMBL3655081","moleculeType":"Small molecule","molecularWeight":"323.42"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL3655081"},"_approvalHistory":[],"_offLabelChecked":true,"publicationCount":0,"_revenueScrapedAt":"2026-04-01 09:48:50.313664+00","recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"_genericFilersChecked":true,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:57:03.890046+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}